Cytokinetics takes on more ispinesib duties
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cytokinetics and GlaxoSmithKline have amended their agreement relating to development of Cytokinetics' kinase spindle protein inhibitors, including the Phase II oncologic ispinesib, Cytokinetics says Nov. 27. The San Francisco biotech plans "a focused development program for ispinesib" that builds on GSK's Phase I/II efforts with the compound. During a second quarter earnings call, CEO James Sabry said the firm would cast a wider net of trials in the wake of ispinesib's Phase II failure in lung cancer (1Pharmaceutical Approvals Monthly August 2006, p. 6)...
You may also be interested in...
Cytokinetics Ispinesib Could Help Fill Gap In HER2 Negative Breast Cancer
Cytokinetics is casting a wider net with its development program for ispinesib following the targeted oncologic’s failure earlier this year in a Phase II lung cancer trial.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.